Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
SAN ANTONIO - bioAffinity Technologies, Inc. (NASDAQ:BIAF; BIAFW) has regained compliance with all applicable Nasdaq continued listing requirements, according to a notice received from the stock exchange. The micro-cap company, currently valued at $12.93 million, has faced significant market challenges, with its stock down nearly 90% year-to-date according to InvestingPro data.
In a letter dated Tuesday, Nasdaq informed the biotechnology company that it has met the minimum closing bid price requirement of $1.00 per share under Listing Rule 5550(a)(2) and the minimum stockholders’ equity requirement of $2.5 million under Listing Rule 5550(b)(1).
The company’s common stock and warrants will continue trading on the Nasdaq Capital Market under the symbols BIAF and BIAFW, respectively.
"We are pleased to have regained full compliance with Nasdaq’s listing standards," said Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies.
Nasdaq has placed the company under a Mandatory Panel Monitor for a one-year period. During this monitoring period, if bioAffinity Technologies fails to comply with the Equity Rule, it will not receive additional time to regain compliance but will have an opportunity to request a new hearing with the Nasdaq Listing Qualifications Hearing Panel.
bioAffinity Technologies develops noninvasive diagnostics for early-stage cancer and other lung diseases. Its first product, CyPath Lung, is marketed as a Laboratory Developed Test for the detection of early-stage lung cancer.
The information in this article is based on a company press release statement.
In other recent news, bioAffinity Technologies, Inc. has reported a 95% increase in sales of its CyPath® Lung diagnostic test for lung cancer in the third quarter of 2025 compared to the previous quarter. This growth is attributed to increased adoption by Veterans’ hospitals and expansion in the mid-Atlantic region. Additionally, for the first nine months of 2025, sales rose 97% compared to the same period in 2024. The company has also successfully closed a $4.8 million public offering, which included 1,921,761 shares of common stock or pre-funded warrants. Each warrant is exercisable for one share of common stock at an exercise price of $0.007 per share. Furthermore, bioAffinity Technologies raised an additional $1.8 million through a registered direct offering, selling 720,000 shares of common stock priced at $2.50 per share. WallachBeth Capital, LLC served as the sole placement agent for this transaction. These developments highlight the company’s recent financial activities and sales performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.